Trial of Dichloroacetate (DCA) in Glioblastoma Multiforme (GBM) (NCT05120284)
🩺 Plain-English Summary (8th-Grade Level)
Conduct a multicenter, open label Phase IIA trial of oral DCA in 40 surgical patients with recurrent GBM who have clinically indicated debulking surgery planned. No patients will be recruited at UF. Patients will be genotyped to establish safe dosing regimens and will be randomized to receive DCA (N=20) or no DCA (N=20) for one week prior to surgery. Deidentified blood and tumor tissue obtained at surgery will be assessed at UF for biochemical markers of DCA dynamics.
Who can join: Review the eligibility criteria below.
Location: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins — Baltimore, Maryland
Age range: 18 Years to 80 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (2 Sites)
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins — Baltimore, Maryland
- Wake Forest University — Winston-Salem, North Carolina
📞 Contact the Study Coordinator
Phone: (855) 694-6725
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Glioblastoma Multiforme
- A Phase 2 Trial of High-Dose Ascorbate in Glioblastoma Multiforme — Iowa City, Iowa
- Subventricular Zone (SVZ) and Temozolomide in Glioblastoma Multiforme — Washington D.C., District of Columbia
- A Study of NanO2™ Combined With Radiation and Temozolomide in Patients With Newly Diagnosed GBM — Tucson, Arizona
- Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients — Phoenix, Arizona
- Trial of Anti-Tim-3 in Combination With Anti-PD-1 and SRS in Recurrent GBM — Stanford, California
Explore by condition: All Glioblastoma Multiforme clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.